The Complementary Role of 68Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma

Min J. Kong, Aaron F. Yang, Sujay A. Vora, Jeffrey S. Ross, Ming Yang

Research output: Contribution to journalArticlepeer-review

Abstract

Contrast-enhanced brain MRI is the imaging modality of choice in diagnosis and posttreatment evaluation, but its role is limited in distinguishing recurrent lesions from postoperative changes. 68Ga-DOTATATE is a somatostatin analog PET tracer that has high affinity to meningioma expressing somatostatin receptor. Methods: In this case series review, we describe 8 patients with brain MRI showing suspected recurrent meningioma who underwent focused 68Ga-DOTATATE PET/CT for radiation treatment planning. Results: The combined brain MRI and PET/CT improved the conspicuity of the lesions and aided radiation treatment planning. The time from the initial surgery to PET/CT varied widely, ranging from 1 to 12 y. Three patients underwent PET/CT shortly after the initial surgery (1-3 y) and underwent targeted radiation therapy. Subsequent imaging showed no evidence of recurrence. Four patients had a prolonged time between the PET/CT and the initial surgery (7-12 y), which showed an extensive tumor burden. All 4 patients died shortly after the last PET/CT scan. Conclusion: 68Ga-DOTATATE PET shows a promising complementary role in detection and treatment planning of recurrent meningioma.

Original languageEnglish (US)
Pages (from-to)348-352
Number of pages5
JournalJournal of nuclear medicine technology
Volume50
Issue number4
DOIs
StatePublished - Dec 1 2022

Keywords

  • DOTATATE
  • meningioma
  • octreotide
  • somatostatin receptor

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'The Complementary Role of 68Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma'. Together they form a unique fingerprint.

Cite this